Xiamen Weizheng Biotechnology Enters Strategic Partnership with Abbott Rapid Diagnostics to Advance POCT Innovation
Abbott
Diagnostic and pharmaceutical product manufacturers
Source: Wiz Biotech
On the morning of May 22, Xiamen Wiz Biotech Co., LTD. held a strategic cooperation signing ceremony with Abbott Rapid Diagnostics, a globally renowned leader in the IVD industry. The aim is to further strengthen the ties between the two parties by upgrading cooperative products and to support and promote the vigorous development of the healthcare industry through practical actions.
Attending the signing ceremony were: Sui Guoyu, Deputy Director of the Haicang Taiwanese Investment Zone Management Committee; Wu Kefen, Standing Deputy Director of the District Investment Promotion Office; Jiang Shengjun, Deputy Director of the District Health Commission; Kang Musheng, Director of the Economic Development Department of the District Industry and Information Technology Bureau; Huang Weibin, Manager of the Investment Department of the Biotechnology Company; Sanjeev Johar, Vice President of Abbott Rapid Diagnostics Asia Pacific; Qiu Jianping, General Manager of Abbott Rapid Diagnostics Greater China; Gan Yehong, Director of Channel Management and Business Excellence of Abbott Rapid Diagnostics Greater China; Qian Lü, Director of Supply Chain and Technical Support of Abbott Rapid Diagnostics Greater China; Lin Zhikeng, Chairman of Wiz Biotech; Wang Xiaozhen, General Manager of Wiz Biotech; Xu Jindui, Deputy General Manager of Wiz Biotech; Liang Jianzong, Deputy General Manager of Wiz Biotech; Shen Xiaojian, Sales Director of Wiz Biotech. Together, they visited the headquarters of Xiamen Wiz Biotech Co., LTD. located in the Xiamen Biomedical Industrial Park.
In the presence of leaders from Haicang District and Xiamen Biomedical Port, Xiamen Wiz Biotech Co., LTD. established a strategic partnership with Abbott Rapid Diagnostics, a global leader in rapid diagnostic solutions. Both parties conducted in-depth discussions on cooperation projects of mutual interest. The two sides will actively explore new business models and technological innovations to achieve sustainable development. Guided by the principles of sincere cooperation and mutual benefit, they are confident in better serving the market and customers, enabling more people to enjoy improved healthcare services.
Xiamen Wiz Biotech Co., LTD., established in July 2013, is a national high-tech enterprise, a national specialized and new "little giant" enterprise, a Fujian provincial technology "little giant" enterprise, a Fujian provincial specialized and new small and medium-sized enterprise, a Xiamen municipal enterprise technology center, a Xiamen municipal specialized and new small and medium-sized enterprise, and an innovative tier company on the NEEQ (Stock code: 839355). As a high-tech company engaged in the research, production, and sales of rapid diagnostic reagents and instruments, it always adheres to the mission of "focusing on diagnostic technology and improving the quality of life," emphasizing technological innovation. It develops POCT diagnostic reagents and instruments with the aim of becoming a leader in the POCT rapid diagnostic medical field. Currently, Wiz Biotech has obtained certifications for over 120 reagent tests both domestically and internationally, covering product series such as gastrointestinal function, infections, infectious diseases, thyroid function, and HIV. The company already possesses a platform for the research and development and production of antigen-antibody raw materials, a mature immunochromatography technology platform, and is actively expanding into platforms such as microfluidics and molecular diagnostics.
Disclaimer: The articles marked with sources in this WeChat are all reprinted, only for sharing, and do not represent the platform's position. If there are any copyright issues, please contact us as soon as possible, and we will correct them at the first time. Thank you.